Editing Event-driven investing (section)

==History==
Event-driven investing "lost on average 1.4 percent in 2015" making them the poorest performers in 2015 despite a record year of mergers and acquisitions partially because funds over purchased only the largest corporate deals.<ref name="bloomberg_2015_Nov_15">{{cite web | url=https://www.bloomberg.com/news/articles/2015-11-15/event-driven-hedge-funds-were-worst-disappointment-says-k2 | title=Event-Driven Hedge Funds Are The 'Worst Disappointment,' Says K2 | publisher=Bloomberg | date=15 November 2015 | access-date=19 December 2015 | author=Hu, Bei}}</ref>

===Healthcare sector===
According to James Elliot at Alan Davis Wealth Management, about 60% of event-driven hedge funds' year-to-date gains...making it the strongest contributor by a large margin."<ref name="efinancialnews_2015">{{cite web | url=http://www.efinancialnews.com/story/2015-08-07/healthcare-injects-life-into-event-driven-hedge-funds | title=Healthcare injects life into event-driven hedge funds | publisher=Financial News | date=7 August 2015 | access-date=19 December 2015 | author=Eschenbacher, Stefanie}}</ref> According to Dealogic, by August health care mergers and acquisitions (M&A) were up 42%, with "an all-time high of $422.8 billion;" in 2014 the high was $429.3 billion for the entire year and also set a record.<ref name="efinancialnews_2015" /> New event-driven hedge funds were launched for example, New York–based Kellner had launched event-driven hedge fund, Capital with Chris Pultz and California-based Omni Partners launched event-driven investing funds such as Omni Event Fund with John Melsom as chief investment officer.<ref name="hedgeweek_2013">{{cite web | url=http://www.hedgeweek.com/2013/09/16/189994/omni-partners-launches-omni-event-fund | title=Omni Partners launches Omni Event Fund | publisher=Hedgeweek | date=16 September 2013 | access-date=19 December 2015}}</ref> Melsom noted that by 2015 there was a lot of consolidation in the healthcare sector especially in pharmaceuticals which gave "exceptionally wide spreads." President [[Barack Obama|Obama]]'s US healthcare reforms led to regulatory uncertainty in healthcare.<ref name="hedgeweek_2013" /> James Elliot's Event Fund returned 34.9% from January through June 2017, 

{{quote|"...helped gains from drug maker Valeant Pharmaceuticals' $11 billion acquisition of specialist drug maker Salix Pharmaceuticals; AbbVie’s acquisition of cancer biotech company Pharmacyclics for $21 billion; and also the decision by US pharmacy benefit manager UnitedHealth to buy rival Catamaran for $12.8 billion."|Hedgeweek August 2015}}